Literature DB >> 31452013

Host-Immune Interactions in JC Virus Reactivation and Development of Progressive Multifocal Leukoencephalopathy (PML).

Amir Khalili1, Michael Craigie1, Martina Donadoni1, Ilker Kudret Sariyer2.   

Abstract

With the advent of immunomodulatory therapies and the HIV epidemic, the impact of JC Virus (JCV) on the public health system has grown significantly due to the increased incidence of Progressive Multifocal Leukoencephalopathy (PML). Currently, there are no pharmaceutical agents targeting JCV infection for the treatment and the prevention of viral reactivation leading to the development of PML. As JCV primarily reactivates in immunocompromised patients, it is proposed that the immune system (mainly the cellular-immunity component) plays a key role in the regulation of JCV to prevent productive infection and PML development. However, the exact mechanism of JCV immune regulation and reactivation is not well understood. Likewise, the impact of host factors on JCV regulation and reactivation is another understudied area. Here we discuss the current literature on host factor-mediated and immune factor-mediated regulation of JCV gene expression with the purpose of developing a model of the factors that are bypassed during JCV reactivation, and thus are potential targets for the development of therapeutic interventions to suppress PML initiation. Graphical Abstract.

Entities:  

Keywords:  Diagnosis; Immunosuppression; JC virus; PML; Reactivation; Therapy

Mesh:

Year:  2019        PMID: 31452013      PMCID: PMC6898772          DOI: 10.1007/s11481-019-09877-8

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  133 in total

Review 1.  Epidemiological evidence and molecular basis of interactions between HIV and JC virus.

Authors:  J R Berger; A Chauhan; D Galey; A Nath
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

2.  Activity of JC virus archetype and PML-type regulatory regions in glial cells.

Authors:  G S Ault
Journal:  J Gen Virol       Date:  1997-01       Impact factor: 3.891

3.  Progressive Multifocal Leukoencephalopathy Following Combined Rituximab-Based Immune-Chemotherapy for Post-transplant Lymphoproliferative Disorder in a Renal Transplant Recipient: A Case Report.

Authors:  M Windpessl; S Burgstaller; A Kronbichler; H Pieringer; O Kalev; A Karrer; M Wallner; J Thaler
Journal:  Transplant Proc       Date:  2018-04       Impact factor: 1.066

4.  Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.

Authors:  Frédéric Bacchetta; Amandine Mathias; Myriam Schluep; Renaud Du Pasquier
Journal:  Mult Scler       Date:  2017-02       Impact factor: 6.312

5.  Structure-based release analysis of the JC virus agnoprotein regions: A role for the hydrophilic surface of the major alpha helix domain in release.

Authors:  A Sami Saribas; Martyn K White; Mahmut Safak
Journal:  J Cell Physiol       Date:  2017-08-28       Impact factor: 6.384

6.  The transcriptional enhancer element, kappa B, regulates promoter activity of the human neurotropic virus, JCV, in cells derived from the CNS.

Authors:  P N Ranganathan; K Khalili
Journal:  Nucleic Acids Res       Date:  1993-04-25       Impact factor: 16.971

7.  Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation.

Authors:  B Ensoli; L Buonaguro; G Barillari; V Fiorelli; R Gendelman; R A Morgan; P Wingfield; R C Gallo
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

8.  Progressive multifocal leukoencephalopathy after natalizumab monotherapy.

Authors:  Hans Lindå; Anders von Heijne; Eugene O Major; Caroline Ryschkewitsch; Johan Berg; Tomas Olsson; Claes Martin
Journal:  N Engl J Med       Date:  2009-09-10       Impact factor: 91.245

9.  Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant.

Authors:  Jesse Waggoner; Tereza Martinu; Scott M Palmer
Journal:  J Heart Lung Transplant       Date:  2009-04       Impact factor: 10.247

10.  Pathologic Findings of Chronic PML-IRIS in a Patient with Prolonged PML Survival Following Natalizumab Treatment.

Authors:  Mai Himedan; Sandra Camelo-Piragua; Elizabeth A Mills; Avneesh Gupta; Rany Aburashed; Yang Mao-Draayer
Journal:  J Investig Med High Impact Case Rep       Date:  2017-09-27
View more
  2 in total

1.  Progressive multifocal leukoencephalopathy associated with chemotherapy induced lymphocytopenia in solid tumors - case report of an underestimated complication.

Authors:  Patrick Mayr; Mathias Lutz; Maximilian Schmutz; Jens Hoeppner; Friederike Liesche-Starnecker; Jürgen Schlegel; Jochen Gaedcke; Rainer Claus
Journal:  Front Oncol       Date:  2022-08-02       Impact factor: 5.738

2.  Determining host factors contributing to the reactivation of JC virus in kidney transplant recipients.

Authors:  Sajedeh Keykhosravi; Masoud Khosravi; Mohammad Shenagari; Elham Hasan-Alizadeh; Mehrdad Mosadegh; Narjes Noori Goodarzi; Ali Monfared; Babak Ashrafkhani; Tolou Hasandokht
Journal:  Virol J       Date:  2022-08-08       Impact factor: 5.913

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.